Exhibit 99.1
| Press Release www.shire.com |  |
Director/PDMR Shareholding
February 24, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transactions by person discharging managerial responsibilities and person closely associated with them
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated them (“PCA”) | ||
| a) | Name | Albert Stroucken / Gerda Stroucken | |
| 2. | Reason for the notification | ||
| a) | Position / status | Non-Executive Director (PDMR) / PCA of Albert Stroucken | |
| b) | Initial notification / amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Shire plc | |
| b) | LEI | 54930005LQRLI2UXRQ59 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”)
| |
| Identification code | ISIN: US82481R1068 | ||
| b) | Nature of the transaction | Joint acquisition of ADSs by PDMR and PCA | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| See appendix below | |||
d)
| Aggregated information - Aggregated volume - Price | Weighted average price | Volume |
$180.96
| 14,000
| ||
| e) | Date of the transaction | February 22, 2017 | |
| f) | Place of the transaction | ARCX, BATS, BYXX, MSCO, NQBX, NQPX, NSDQ, XEDG | |
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Appendix
| Place of the transaction | Price(s) | Volume(s) |
| ARCX | $181.13 | 100 |
| ARCX | $180.93 | 47 |
| ARCX | $180.93 | 53 |
| ARCX | $180.91 | 100 |
| ARCX | $181.19 | 100 |
| ARCX | $181.17 | 100 |
| ARCX | $181.47 | 100 |
| ARCX | $181.37 | 100 |
| ARCX | $181.63 | 50 |
| ARCX | $181.45 | 100 |
| ARCX | $181.51 | 100 |
| ARCX | $181.51 | 100 |
| ARCX | $180.90 | 100 |
| ARCX | $180.98 | 100 |
| ARCX | $180.77 | 100 |
| ARCX | $180.57 | 100 |
| ARCX | $180.81 | 100 |
| ARCX | $180.83 | 100 |
| ARCX | $180.83 | 100 |
| BATS | $181.46 | 100 |
| BATS | $180.98 | 30 |
| BATS | $180.98 | 70 |
| BATS | $180.98 | 100 |
| BATS | $180.85 | 100 |
| BATS | $180.83 | 100 |
| BYXX | $181.33 | 100 |
| BYXX | $181.32 | 100 |
| BYXX | $181.44 | 12 |
| BYXX | $181.44 | 14 |
| BYXX | $180.85 | 100 |
| MSCO | $181.30 | 100 |
| MSCO | $181.95 | 100 |
| MSCO | $181.19 | 100 |
| MSCO | $180.89 | 300 |
| MSCO | $180.70 | 100 |
| MSCO | $180.75 | 100 |
| MSCO | $180.57 | 100 |
| MSCO | $180.47 | 100 |
| MSCO | $180.45 | 200 |
| MSCO | $180.63 | 100 |
| MSCO | $180.61 | 100 |
| MSCO | $180.52 | 100 |
| MSCO | $180.57 | 100 |
| MSCO | $180.50 | 100 |
| MSCO | $180.63 | 200 |
| MSCO | $180.82 | 100 |
| MSCO | $180.91 | 200 |
| MSCO | $180.91 | 200 |
| MSCO | $180.98 | 100 |
| MSCO | $180.91 | 400 |
| MSCO | $180.84 | 100 |
| MSCO | $180.88 | 100 |
| MSCO | $180.80 | 200 |
| MSCO | $180.84 | 100 |
| MSCO | $180.84 | 200 |
| MSCO | $180.69 | 200 |
| MSCO | $180.94 | 300 |
| MSCO | $180.98 | 100 |
| MSCO | $180.95 | 200 |
| MSCO | $180.83 | 100 |
| MSCO | $180.82 | 200 |
| MSCO | $181.04 | 3 |
| NQBX | $180.79 | 100 |
| NQBX | $180.96 | 100 |
| NQPX | $181.01 | 100 |
| NSDQ | $181.02 | 100 |
| NSDQ | $181.13 | 100 |
| NSDQ | $180.51 | 100 |
| NSDQ | $180.26 | 26 |
| NSDQ | $180.26 | 74 |
| NSDQ | $180.33 | 100 |
| NSDQ | $180.41 | 100 |
| NSDQ | $181.20 | 100 |
| NSDQ | $181.21 | 100 |
| NSDQ | $180.90 | 100 |
| NSDQ | $181.03 | 100 |
| NSDQ | $181.26 | 100 |
| NSDQ | $181.31 | 100 |
| NSDQ | $181.31 | 100 |
| NSDQ | $181.84 | 100 |
| NSDQ | $181.67 | 100 |
| NSDQ | $181.65 | 100 |
| NSDQ | $181.40 | 100 |
| NSDQ | $181.53 | 15 |
| NSDQ | $181.53 | 85 |
| NSDQ | $181.52 | 33 |
| NSDQ | $181.52 | 67 |
| NSDQ | $181.38 | 56 |
| NSDQ | $181.38 | 44 |
| NSDQ | $181.55 | 100 |
| NSDQ | $181.43 | 100 |
| NSDQ | $181.39 | 15 |
| NSDQ | $181.39 | 85 |
| NSDQ | $181.37 | 100 |
| NSDQ | $181.41 | 100 |
| NSDQ | $181.43 | 100 |
| NSDQ | $181.29 | 100 |
| NSDQ | $180.83 | 100 |
| NSDQ | $180.82 | 1 |
| NSDQ | $180.82 | 99 |
| NSDQ | $180.98 | 100 |
| NSDQ | $181.07 | 100 |
| NSDQ | $180.76 | 100 |
| NSDQ | $180.76 | 8 |
| NSDQ | $180.76 | 92 |
| NSDQ | $181.02 | 100 |
| NSDQ | $180.62 | 100 |
| NSDQ | $180.38 | 100 |
| NSDQ | $180.29 | 100 |
| NSDQ | $180.65 | 100 |
| NSDQ | $180.69 | 39 |
| NSDQ | $180.69 | 61 |
| NSDQ | $181.00 | 30 |
| NSDQ | $181.02 | 70 |
| NSDQ | $180.85 | 100 |
| NSDQ | $180.67 | 100 |
| NSDQ | $180.94 | 8 |
| NSDQ | $180.94 | 92 |
| NSDQ | $180.83 | 100 |
| NSDQ | $180.84 | 100 |
| NSDQ | $180.83 | 80 |
| NSDQ | $180.83 | 100 |
| NSDQ | $180.83 | 100 |
| NSDQ | $180.83 | 100 |
| NSDQ | $180.83 | 20 |
| NSDQ | $180.83 | 100 |
| NSDQ | $180.82 | 100 |
| NSDQ | $181.01 | 77 |
| NSDQ | $181.01 | 77 |
| NSDQ | $181.01 | 23 |
| NSDQ | $181.01 | 16 |
| NSDQ | $181.01 | 7 |
| NSDQ | $181.01 | 93 |
| NSDQ | $181.01 | 7 |
| XEDG | $180.61 | 100 |
| XEDG | $181.27 | 5 |
| XEDG | $181.27 | 95 |
| XEDG | $181.08 | 2 |
| XEDG | $181.08 | 98 |
| XEDG | $180.86 | 57 |
| XEDG | $180.86 | 43 |
| XEDG | $180.95 | 100 |
| XEDG | $181.17 | 100 |
| XEDG | $181.12 | 100 |
| XEDG | $180.92 | 100 |
| XEDG | $180.77 | 21 |
| XEDG | $180.87 | 100 |
| XEDG | $180.83 | 100 |
| Place of the transaction | Weighted average price | Aggregated volume |
| ARCX | $181.09 | 1,750 |
| BATS | $181.02 | 500 |
| BYXX | $181.19 | 326 |
| MSCO | $180.83 | 4,703 |
| NQBX | $180.88 | 200 |
| NQPX | $181.01 | 100 |
| NSDQ | $181.01 | 5,400 |
| XEDG | $180.96 | 1,021 |
| Total | $180.96 | 14,000 |
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Ian Karp | ikarp@shire.com | +1 781 482 9018 |
| Robert Coates | rcoates@shire.com | +44 1256 894874 |
| Media | ||
| Lisa Adler | lisa.adler@shire.com | +1 617 588 8607 |
| Debbi Ford | debbi.ford@shire.com | +1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com